Day: December 19, 2019

L’accord de rachat d’actions d’un montant de 200 millions d’euros conclu le 26 mars 2019 avec Goldman Sachs International (« Goldman Sachs »), mis en œuvre le 17 avril 2019, a pris fin le 17 décembre 2019.Entre le 17 avril 2019 et le 17 décembre 2019, Wendel a acquis, dans le cadre de ce programme, un total ajusté de 1 645 338 de ses propres actions (représentant 3,55 % du capital social avant le lancement du programme), pour un prix moyen ajusté de 121,5555 euros.Pour mémoire, le 23 avril 2019, Wendel avait versé 200 millions d’euros à Goldman Sachs et avait reçu 1 169 399 de ses propres actions ordinaires. Ces actions avaient été annulées le 25 avril 2019.Au terme de l’accord,...

TORONTO, Dec. 19, 2019 (GLOBE NEWSWIRE) — CellCube Energy Storage Systems Inc. (“CellCube” or the “Company”) (CSE:CUBE), wishes to provide an update on the sale of Enerox GmbH (“Enerox”), previously announced on November 12, 2019 to a consortium of investors which includes Bushveld Minerals (the “Consortium”).The sale of Enerox is progressing as previously described and Cellcube would like to announce that as of today, the Consortium has signed the initial sale and purchase agreement (“ISPA”). In terms of the ISPA, the Consortium have acquired 24.90 per cent of the issued share capital of Enerox for €150,000 from CellCube (the “Seller”), and to date the Consortium has provided Enerox with €600,000.As previously announced, the Consortium has been granted...

PARIS and NEW YORK, Dec. 19, 2019 (GLOBE NEWSWIRE) — Quantum Genomics (Euronext Growth – FR0011648971 – ALQGC, OTCQX – QNNTF), a biopharmaceutical company specializing in developing a new drug class that directly targets the brain to treat resistant hypertension and heart failure, today announced the initiation of its pivotal Phase III FRESH study (Firibastat in treatment-RESistant Hypertension) in difficult-to-treat1 and resistant2 hypertension. The trial is being conducted in partnership with Biolab Sanus Pharmaceuticals, as announced on December 9, 2019.This efficacy study will enroll 500 subjects with difficult-to-treat or resistant hypertension who will be randomized to receive a blind treatment with firibastat (500 mg BID), or placebo, for three months on top of their current therapy, in approximately...

Elmwood Park, NJ, Dec. 19, 2019 (GLOBE NEWSWIRE) — BioReference Laboratories, Inc., an OPKO Health Company, along with its genetics and genomics laboratory, GeneDx, Inc., and oncology, urology and women’s health division, GenPath Diagnostics, are pleased to provide a 2019 business update, highlighting new tests that lead to faster diagnoses, payer relationships that provide greater access to care, and new tools that empower patients to take responsibility of their health. Work completed by the company this year reinforces its commitment to healthcare providers, patients and payers, as well as the local community and its employees.“The healthcare industry is moving towards preventive, convenient and personalized care, and the landscape is shifting to place patients at the forefront of decisions regarding their health....

ROCKVILLE, MD, Dec. 19, 2019 (GLOBE NEWSWIRE) — MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company has submitted a Biologics License Application (BLA) for margetuximab, an investigational, Fc-engineered, monoclonal antibody that targets HER2. The margetuximab BLA is for the treatment of patients with metastatic HER2-positive breast cancer in combination with chemotherapy. The submission is based on the safety and efficacy results of the pivotal phase 3 SOPHIA study, which were first presented at the 2019 American Society of Clinical Oncology annual meeting, with updated data recently presented at the 2019 San Antonio Breast Cancer Symposium.“As...

Calendrier de communication financière 2020Bezons, le 19 décembre 2019 – 18h00 – RIBER, un leader mondial d’équipement pour l’industrie des semi-conducteurs, annonce son agenda indicatif de communication financière pour l’exercice 2020.*Sous réserve de modification. Publication après clôture du marché.A propos de RIBER :RIBER est un leader mondial d’équipement pour l’industrie des semiconducteurs. L’entreprise conçoit et fabrique des systèmes d’épitaxie par jets moléculaires (MBE) ainsi que des évaporateurs destinés à l’industrie des semi-conducteurs. Elle offre également à ses clients un support technique et scientifique en assurant la maintenance...

MAROUSSI, ATHENS, Greece, Dec. 19, 2019 (GLOBE NEWSWIRE) — Euroseas Ltd. (NASDAQ: ESEA, the “Company” or “Euroseas”), an owner and operator of container carrier vessels and provider of seaborne transportation for containerized cargoes,  announced today that it has completed a 1-for-8 reverse stock split, effective at the close of trading on December 18, 2019. The Company’s common shares begin trading on a split-adjusted basis on December 19, 2019. The reverse stock split was undertaken with the objective of meeting the minimum $1.00 per share requirement for listing the Company’s common stock on the Nasdaq Capital Market.Fractional shares will be rounded up to the next full share. Each common shareholder will hold the same percentage of the outstanding common shares immediately following...

Preliminary Announcement of Final Results for the year ended 30 September 2019Strategic reportThe report has been prepared by the Directors in accordance with the requirements of Section 414A of the Companies Act 2006.Financial highlights* Calculated using the AIC’s “Ongoing Charges” methodology.Chairman’s statementIntroductionFollowing the success of our offer for subscription which raised £25 million, I would like to welcome a large number of new shareholders.PerformanceAt 30 September 2019, the net asset value (NAV) was 70.60 pence per share which after adjusting for the dividends paid gives a NAV total return since inception of 125.75 pence. The earnings per share combined return for the year was a loss of 11.05 pence (comprising a revenue loss of 0.01 pence and a capital loss of 11.04 pence). The NAV total...

La Banque Postale and the Groupama Group have signed a non-binding memorandum of understanding covering the acquisition by La Banque Postale of Groupama’s 35% interest in La Banque Postale IARD (LBP IARD) and their extended cooperation in the areas of legal protection and assistance services.LBP IARD, which was set up in late 2009 as a joint venture between La Banque Postale and the Groupama Group, markets property & casualty insurance products and services to La Banque Postale’s retail customers. With over 500 employees and an insurance portfolio comprising 1.8 million policies, LBP IARD has become an independent full-service insurance company.Contractual relations between LBP IARD and the Groupama Group also include service agreements and reinsurance treaties with two Groupama subsidiaries, Groupama PJ (for legal...

La Banque Postale et le Groupe Groupama annoncent avoir signé un protocole d’accord non-engageant pour l’acquisition, par La Banque Postale, de la participation de 35% détenue par Groupama dans La Banque Postale IARD et la prolongation de leur coopération dans les domaines de la protection juridique et de l’assistance.Créée conjointement fin 2009 par La Banque Postale et le Groupe Groupama, LBP IARD commercialise une offre de produits et services d’assurance-dommages à destination des clients particuliers de La Banque Postale.Avec plus de 500 collaborateurs au service d’un portefeuille de 1,8 million de contrats, La Banque Postale IARD est devenue une compagnie d’assurance autonome de plein exercice.Les relations contractuelles entre LBP IARD et le Groupe Groupama...